Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics—Relevance to Glioma

Advances in metabolic imaging techniques have allowed for more precise characterization of gliomas, particularly as it relates to tumor recurrence or pseudoprogression. Furthermore, the emerging field of radiogenomics where radiographic features are systemically correlated with molecular markers has the potential to achieve the holy grail of neuro-oncologic neuro-radiology, namely molecular diagnosis without requiring tissue specimens. In this section, we will review the utility of metabolic imaging and discuss the current state of the art related to the radiogenomics of glioblastoma.

[1]  San Bernardino,et al.  SURVIVAL ANALYSIS , 2020, Statistical Methods for Biomedical Research.

[2]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[3]  F. Q. Ribeiro The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[4]  Junia C Costa,et al.  Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  I. Kovanlikaya,et al.  The Added Prognostic Value of Metabolic Tumor Size on FDG‐PET at First Suspected Recurrence of Glioblastoma Multiforme , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[6]  G. Liberman,et al.  Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study , 2017, Journal of Neuro-Oncology.

[7]  Martin Glas,et al.  Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma , 2016, Oncotarget.

[8]  R. Colen,et al.  Radiomics in Brain Tumors: An Emerging Technique for Characterization of Tumor Environment. , 2016, Magnetic resonance imaging clinics of North America.

[9]  E. Maher,et al.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Brigitta G. Baumert,et al.  Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1) , 2016, BMC Cancer.

[11]  Martin Sill,et al.  Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. , 2016, Radiology.

[12]  B. Małkowski,et al.  Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Ginu A. Thomas,et al.  Diffusion Weighted Magnetic Resonance Imaging Radiophenotypes and Associated Molecular Pathways in Glioblastoma. , 2016, Neurosurgery.

[14]  Hui Zhang,et al.  The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis , 2016, European Radiology.

[15]  F. Mulero,et al.  Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas , 2016, PloS one.

[16]  H. Aerts,et al.  Applications and limitations of radiomics , 2016, Physics in medicine and biology.

[17]  H. You,et al.  Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination , 2016, Medicine.

[18]  K. Peck,et al.  A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. , 2016, Neuro-oncology.

[19]  D. Mankoff,et al.  ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI , 2016, Clinical Cancer Research.

[20]  T. Poeppel,et al.  68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin , 2016, The Journal of Nuclear Medicine.

[21]  L. Deangelis,et al.  Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.

[22]  Daniel J. Brat,et al.  Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment , 2016, Chinese journal of cancer.

[23]  E. Shimosegawa,et al.  Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas , 2016, American Journal of Neuroradiology.

[24]  R. Fimmers,et al.  Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET , 2015, Clinical Cancer Research.

[25]  Keith L. Ligon,et al.  Somatic mutations associated with MRI-derived volumetric features in glioblastoma , 2015, Neuroradiology.

[26]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[27]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[28]  N. Delcroix,et al.  [18F]-fluoro-l-thymidine PET and advanced MRI for preoperative grading of gliomas , 2015, NeuroImage: Clinical.

[29]  L. Recht,et al.  Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. , 2015, Radiology.

[30]  David A Gutman,et al.  Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death. , 2015, Radiology.

[31]  W. Pope Genomics of brain tumor imaging. , 2015, Neuroimaging clinics of North America.

[32]  Xiaofeng Zhou,et al.  Bmi1 Drives Stem-Like Properties and is Associated with Migration, Invasion, and Poor Prognosis in Tongue Squamous Cell Carcinoma , 2015, International journal of biological sciences.

[33]  S. Nelson,et al.  Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. , 2014, Cancer research.

[34]  T. Nakada,et al.  Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy , 2014, Acta neuropathologica communications.

[35]  John O. Prior,et al.  Combination of MRI and dynamic FET PET for initial glioma grading , 2014, Nuklearmedizin.

[36]  Max Wintermark,et al.  Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project , 2014, BMC Medical Genomics.

[37]  S. Plevritis,et al.  Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. , 2014, Radiology.

[38]  M. Kuo,et al.  Behind the numbers: Decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations. , 2014, Radiology.

[39]  P. Larson,et al.  Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.

[40]  S. Deng,et al.  Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis , 2013, Nuclear medicine communications.

[41]  T. Nihashi,et al.  Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis , 2013, American Journal of Neuroradiology.

[42]  Benjamin M Ellingson,et al.  Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. , 2013, Neuro-oncology.

[43]  T. Cloughesy,et al.  Probabilistic Radiographic Atlas of Glioblastoma Phenotypes , 2013, American Journal of Neuroradiology.

[44]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[45]  Ricardo J. Komotar,et al.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? , 2013, Journal of Neuro-Oncology.

[46]  Andre Dekker,et al.  Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.

[47]  O. Chinot,et al.  FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. , 2012, Neuro-oncology.

[48]  D. Haas-Kogan,et al.  Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. , 2012, Neuro-oncology.

[49]  George Fountzilas,et al.  Volumetric and MGMT parameters in glioblastoma patients: Survival analysis , 2012, BMC Cancer.

[50]  M. Chaumeil,et al.  Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma , 2012, NeuroImage.

[51]  D. Haynor,et al.  Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects , 2012, Journal of magnetic resonance imaging : JMRI.

[52]  Ferenc A. Jolesz,et al.  Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.

[53]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[54]  P. Sundgren,et al.  MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. , 2011, Academic radiology.

[55]  Rakesh Kumar,et al.  F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study , 2011, Neuroradiology.

[56]  C. James,et al.  Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging , 2011, Journal of magnetic resonance imaging : JMRI.

[57]  K. Kang,et al.  Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI , 2010, Clinical Neurology and Neurosurgery.

[58]  M. J. van den Bent Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta neuropathologica.

[59]  Martin J. Bent,et al.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.

[60]  M. Senda,et al.  Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  R. Gonzalez,et al.  Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. , 2010, Academic radiology.

[62]  Sylvia Drabycz,et al.  An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging , 2010, NeuroImage.

[63]  H. Lanfermann,et al.  DIAGNOSTIC VALUE OF PROTON MAGNETIC RESONANCE SPECTROSCOPY IN THE NONINVASIVE GRADING OF SOLID GLIOMAS: COMPARISON OF MAXIMUM AND MEAN CHOLINE VALUES , 2009, Neurosurgery.

[64]  Sylvia Drabycz,et al.  Predicting MGMT Methylation Status of Glioblastomas from MRI Texture , 2009, MICCAI.

[65]  Wei Chen,et al.  18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. , 2009, European journal of radiology.

[66]  P. Sundgren,et al.  Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. , 2009, AJR. American journal of roentgenology.

[67]  Shigeaki Higashiyama,et al.  Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy , 2008, Journal of Nuclear Medicine.

[68]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[69]  J. Llamas-Elvira,et al.  Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[70]  Chen Wei-an,et al.  Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET , 2007, Journal of Neuro-Oncology.

[71]  Hong Liu,et al.  Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury , 2007, Journal of Neuro-Oncology.

[72]  Isabelle Salmon,et al.  Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: Preliminary results , 2006, Journal of magnetic resonance imaging : JMRI.

[73]  B. Gulyás,et al.  Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas , 2006, Journal of the Neurological Sciences.

[74]  Wei Chen,et al.  18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  B. Nan,et al.  Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. , 2005, AJR. American journal of roentgenology.

[76]  W. Koch,et al.  Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas , 2005, Neurosurgery.

[77]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  Hans-Jakob Steiger,et al.  Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. , 2005, Journal of neurosurgery.

[79]  Isabelle Salmon,et al.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  Jörg-Christian Tonn,et al.  Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[81]  M. Morino,et al.  Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery —In malignant glioma— , 2004, Annals of nuclear medicine.

[82]  D. Hwang,et al.  Prediction of Pathology and Survival by FDG PET in Gliomas , 2003, Journal of Neuro-Oncology.

[83]  J. Edmeads,et al.  The Clinician's Perspective , 2001, Headache.

[84]  G. Barnett,et al.  The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery , 2001, International journal of cancer.

[85]  U. Spetzger,et al.  Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses , 2001, European Journal of Nuclear Medicine.

[86]  N. Kuwata,et al.  Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining , 1999, Neurosurgical Review.

[87]  B. Drayer,et al.  Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.

[88]  R. Maciunas,et al.  Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.

[89]  W D Heiss,et al.  FDG‐PET as a Prognostic Indicator in Radiochemotherapy of Glioblastoma , 1993, Journal of computer assisted tomography.

[90]  R. Coleman,et al.  Serial FDG‐PET Studies in the Prediction of Survival in Patients with Primary Brain Tumors , 1993, Journal of computer assisted tomography.

[91]  J. Bruner,et al.  Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors , 1993, Annals of neurology.

[92]  D. Podoloff,et al.  Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. , 1992, Radiographics : a review publication of the Radiological Society of North America, Inc.

[93]  P. Gutin,et al.  PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. , 1988, Journal of neurosurgery.

[94]  C. Kufta,et al.  Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. , 1987, AJR. American journal of roentgenology.

[95]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[96]  J. Brenton,et al.  Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. , 2017, Clinical radiology.

[97]  L. Recht,et al.  Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. , 2016, Radiology.

[98]  G. Barger,et al.  Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI , 2015, Journal of Neuro-Oncology.

[99]  S. Plevritis,et al.  Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. , 2015, Radiology.

[100]  G. Tabatabai,et al.  In vivo visualization of prostate-specific membrane antigen in glioblastoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  Benjamin M. Ellingson,et al.  Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.

[102]  Quanshi Wang,et al.  ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. , 2012, Chinese medical journal.

[103]  I. Mahé,et al.  A Prospective Study , 2009 .

[104]  Hayden O. Kepley,et al.  Preliminary results , 2007 .

[105]  R. DeLaPaz,et al.  Multisection 1H Magnetic Resonance Spectroscopic Imaging Assessment of Glioma Response to Chemotherapy , 2005, Journal of Neuro-Oncology.

[106]  Koen Van Laere,et al.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[107]  Susan M. Chang,et al.  Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. , 2001, Magnetic resonance imaging.